1.625USD-4.69%Mkt Cap: 97.72M USDP/E: —Last update: 2026-06-01
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, wh…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap97.72M USD
Enterprise Value56.07M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.85M USD
Revenue/Share—
Last Price1.625 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS01438T1060
Valuation
P/E (Trailing)—
P/E (Forward)-9.72
PEG—
EV/EBITDA-1.99
EV/Revenue—
P/S—
P/B2.50
EPS (TTM)-0.45
EPS (Forward)-0.18
52W Range
1.07011% of range6.175
52W High6.175 USD
52W Low1.070 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.49%
ROA-46.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.35M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-20.06%
Net Debt-49.49M USD
Net Debt/EBITDA1.76
Balance Sheet
Debt/Equity0.35
Current Ratio2.72
Quick Ratio2.67
Book Value/Sh0.6990 USD
Cash/Share1.078 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)7.600 USD
Target Range2.000 USD – 13.00 USD
# Analysts5
Ownership
Shares Out.60.32M
Float52.93M
Insiders3.18%
Institutions62.79%
Short Interest
Short Ratio7.0d
Short % Float12.98%
Short % Out.12.57%
Shares Short7.58M
Short (prev mo.)5.54M
Technical
SMA 501.691 (-3.9%)
SMA 2004.263 (-61.9%)
Beta1.15
S&P 52W Chg27.94%
Avg Vol (30d)928.44K
Avg Vol (10d)981.49K
Technical Indicators
RSI (14)48.2
MACD-0.0562
MACD Signal-0.0947
MACD Hist.+0.0385
BB Upper1.816 USD
BB Middle1.667 USD
BB Lower1.519 USD
BB Width17.84%
ATR (14)0.1176 USD
Vol Ratio (20d)0.38x